This week's roundup includes CEO appointments by Gyroscope Therapeutics, Urovant Sciences and Nevoii Pharmaceuticals, in addition to various other high-level appointments by companies including, Horizon Pharma, Veloxis Pharmaceuticals, Modus Therapeutics and Adherium.

Evotec has signed two more R&D deals with French major Sanofi that it hopes will help it move on from previous R&D disappointments.

Evotec’s deal with the French drugmaker to develop stem cell-based treatments for diabetes takes on even more importance following the demise of the biotech’s two lead proprietary candidate therapies.

Germany's Evotec has taken legal steps against Israel's Andromeda Biotech in an effort to recoup its losses following Andromeda's falsification of trial results for diabetes drug DiaPep277. Evotec's stock took a dive when the deception came to light earlier in September and has yet to recover.